Solid Biosciences SLDB 深 滬
已收盤 10-31 16:00:00 美东时间
5.39
+0.080
+1.51%
華盛通- 最 高5.55
- 今 開5.36
- 成交量 80.15万股
- 最 低 5.21
- 昨 收 5.31
- 總市值 4.20亿
- 52周最高 7.37
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 2.41
- 委 比 55.00%
- 總股本 7786.91万
- 歷史最高 822.60
- 量 比 1.07
- 振 幅 6.40%
- 歷史最低 1.81
- 每 手 1
- 風險率 1.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Solid Biosciences to Participate at Upcoming Investor Conferences
<p>Solid Biosciences Inc. announced its participation in two upcoming investor conferences: the 2025 Truist Securities BioPharma Symposium and the 2nd Annual Guggenheim Healthcare Innovation Conference. Dr. Gabriel Brooks, the company’s Chief Medical Officer, will discuss precision medicine, including treatments for Duchenne muscular dystrophy (DMD) and Friedreich’s ataxia (FA), during the symposium. The management team will also engage in one-on...
10-30 12:00
Solid Biosciences to Present at Upcoming Scientific Meetings
Solid Biosciences will present data from its neuromuscular and cardiac programs at the World Muscle Society 2025 Annual International Congress in Vienna and the European Society of Gene & Cell Therapy 2025 Annual Congress in Seville. The presentations will highlight the potential of its innovative pipeline and proprietary AAV-SLB101 capsid. The company aims to engage with the scientific and medical communities at these events.
10-01 12:00
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
Solid Biosciences将在2025年9月26日至28日在意大利斯特雷萨举行的第26届神经肌肉研究组年度会议上展示其基因疗法SGT-003的最新数据。SGT-003是一种用于治疗杜兴氏肌肉营养不良症的下一代微小 dystrophin 基因疗法。会议将展示Phase 1/2 INSPIRE DUCHENNE试验的90天活检数据和安全性更新。SGT-003采用了专有的AAV-SLB101载体，旨在减少肝脏 targeting 并提高心脏和骨骼肌的 transduction。公司已与25家公司合作使用AAV-SLB101，并计划扩展至更多组织。
09-25 12:00
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Solid Biosciences与Kinea Bio达成非独家全球许可协议，授权其使用专有AAV-SLB101衣壳用于开发KNA-155基因疗法治疗肢带型 muscular dystrophy 2B/R2。Solid将获得预付款、开发和销售里程碑款项及净销售额分成。AAV-SLB101具有增强肌肉趋向性和减少肝脏分布的特点，在临床前和早期临床数据显示良好安全性。Solid现已有25项合作协议，旨在扩大AAV-SLB101的使用范围。
09-23 12:00
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 18, 2025 /PRNewswire/ -- USA News Group News Commentary –Today, Americans over 65 command $22,...
09-18 21:10
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. will participate in four investor conferences in September 2025, with CEO Bo Cumbo engaging in fireside chats at each event. The chats will be live streamed via webcasts available on the company's Events page, with replays archived for 90 days. Institutional investors can schedule one-on-one meetings with management through the conference hosts. Solid Biosciences focuses on developing gene therapies for rare neuromuscular a...
08-28 12:00
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $14
Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17 to $14.
08-13 22:44
Solid Biosciences Q2 EPS $(0.42) Beats $(0.53) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.53) by 20 percent. This is a 31.15 percent increase over losses of $(0.61) per share from
08-13 04:36
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Solid Biosciences reported Q2 2025 financials with $268.1M in cash and updates on their neuromuscular and cardiac programs. SGT-003 for Duchenne has dosed 15 participants across multiple cohorts with no treatment-emergent SAEs. SGT-212 for FA and SGT-501 for CPVT are expected to initiate Phase 1b trials in Q4 2025. The company anticipates FDA discussions for SGT-003 in Q4 2025 and expects a strong cash runway into H1 2027.
08-12 20:07
